{"protocolSection": {"identificationModule": {"nctId": "NCT04327024", "orgStudyIdInfo": {"id": "D5496C00005"}, "secondaryIdInfos": [{"id": "2019-004862-16", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study of Verinurad in Heart Failure With Preserved Ejection Fraction", "officialTitle": "A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction", "acronym": "AMETHYST"}, "statusModule": {"statusVerifiedDate": "2023-06", "overallStatus": "COMPLETED", "startDateStruct": {"date": "2020-05-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-04-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-04-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-03-13", "studyFirstSubmitQcDate": "2020-03-27", "studyFirstPostDateStruct": {"date": "2020-03-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-04-26", "resultsFirstSubmitQcDate": "2023-06-12", "resultsFirstPostDateStruct": {"date": "2023-06-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-06-12", "lastUpdatePostDateStruct": {"date": "2023-06-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction", "detailedDescription": "Evidence shows independent associations between hyperuricaemia and the risk of cardio-renal conditions, including heart failure (HF). Serum uric acid (sUA) is also a strong prognostic factor and correlates with other markers of poor prognosis in HF patients with preserved ejection fraction (HFpEF), and an estimated 1/2-2/3 of HFpEF patients have hyperuricaemia. HFpEF is a microvascular disease likely partly driven by endothelial dysfunction and inflammation in coronary vessel walls. Uric acid crystals have been identified in coronary vessel walls in some hyperuricaemic patients.\n\nUric acid transporter 1 (URAT1) is responsible for reabsorption of uric acid (UA) in the proximal tubule. Inhibition of URAT1 results in increased urinary excretion of UA and lowering of uric acid in the blood. Verinurad is a novel URAT1 inhibitor in Phase 2 development for chronic kidney disease (CKD) and HF. Verinurad combined with the xanthine oxidase (XO) inhibitors (XOI) febuxostat or allopurinol has been shown to lower sUA in patients with recurrent gout in Phase 2 studies by up to approximately 80%.\n\nThe primary objective of this Phase 2 study is to assess the effect of a combination of verinurad and allopurinol on exercise capacity in patients with HFpEF.\n\nThe secondary objectives are to assess effect of combination of verinurad and allopurinol in comparison to allopurinol monotheraphy on excercise capacity dwhich will be measured in peak VO2 as well as effect of verinurad and allopurinol compared to placebo and to allopurinol monotheraphy on Kansas City cardiomyopathy questionnaire (KCCQ)-total symptom score (TSS). A sub-study aims to investigate the relationship between UA crystals and inflammation."}, "conditionsModule": {"conditions": ["Heart Failure With Preserved Ejection Fraction (HFpEF)"], "keywords": ["Phase 2,", "Double-Blind,", "Placebo and Active Control,", "Verinurad,", "Allopurinol,", "HFpEF,", "Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 159, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Verinurad 12 + allopurinol", "type": "EXPERIMENTAL", "description": "Dose \\[mg\\] verinurad/allopurinol:\n\nStep 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300", "interventionNames": ["Drug: Verinurad", "Drug: Allopurinol"]}, {"label": "Allopurinol alone", "type": "EXPERIMENTAL", "description": "Dose \\[mg\\] verinurad/allopurinol:\n\nStep 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300", "interventionNames": ["Drug: Allopurinol"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo \\[mg\\] in 3 steps 0/0", "interventionNames": ["Drug: Placebo for verinurad", "Drug: Placebo for allopurinol"]}], "interventions": [{"type": "DRUG", "name": "Verinurad", "description": "The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.\n\nDrug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol.", "armGroupLabels": ["Verinurad 12 + allopurinol"], "otherNames": ["verinurad titration 3 - 7.5 - 12mg", "allopurinol titration 100 - 200 - 300 mg"]}, {"type": "DRUG", "name": "Allopurinol", "description": "Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol", "armGroupLabels": ["Allopurinol alone", "Verinurad 12 + allopurinol"], "otherNames": ["allopurinol titration 100 - 200 - 300 mg"]}, {"type": "DRUG", "name": "Placebo for verinurad", "description": "Matching Capsule", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo"]}, {"type": "DRUG", "name": "Placebo for allopurinol", "description": "Matching tablet", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model)", "description": "Mean change from baseline in peak VO2 at Week 32 between the treatment groups was compared using change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and baseline peak VO2 included as covariate.\n\nH0: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs placebo) = 0 Ha: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs placebo) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.\n\nSince this was the first test in the hierarchical test sequence and endpoint was not rejected at a two-sided 0.05 level, the testing sequence did not continue.", "timeFrame": "From baseline to Week 32"}], "secondaryOutcomes": [{"measure": "Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad+ Allopurinol Compared to Allopurinol Monotherapy (ANCOVA Model)", "description": "Mean change from baseline in peak VO2 at Week 32 between the treatment groups was compared using change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and baseline peak VO2 included as covariate.\n\nH0: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs allopurinol) = 0 Ha: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs allopurinol) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.", "timeFrame": "From baseline to Week 32"}, {"measure": "Change From Baseline at Week 32 in KCCQ-TSS in Verinurad+ Allopurinol Compared to Placebo (MMRM)", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item assessment that measures the patient's perception of their health status, which includes heart failure-related symptoms (frequency, burden, recent change), impact on physical and social function, self-efficacy and knowledge, and how the patient's heart failure affects their quality of life. The Total Symptom Score (TSS) averages the frequency domain and the symptom burden domain subscales, which each range from 0 to 100. The TSS ranges from 0-100 (higher scores = better health status).\n\nMean change from baseline in KCCQ-TSS at Week 32 between the treatment groups was compared using MMRM analysis, with change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS included as covariates.\n\nThe number analyzed at each timepoint represents the number of subjects with data at each visit.", "timeFrame": "From baseline to Week 22 and Week 32"}, {"measure": "Change From Baseline at Week 32 in KCCQ-TSS in Verinurad+ Allopurinol Compared to Allopurinol Monotherapy (MMRM)", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item assessment that measures the patient's perception of their health status, which includes heart failure-related symptoms (frequency, burden, recent change), impact on physical and social function, self-efficacy and knowledge, and how the patient's heart failure affects their quality of life. The Total Symptom Score (TSS) averages the frequency domain and the symptom burden domain subscales, which each range from 0 to 100. The TSS ranges from 0-100 (higher scores = better health status).\n\nMean change from baseline in KCCQ-TSS at Week 32 between the treatment groups was compared using MMRM analysis, with change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS included as covariates.\n\nThe number analyzed at each timepoint represents the number of subjects with data at each visit.", "timeFrame": "From baseline to Week 22 and Week 32"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be \u2265 40 years of age at the time of signing the ICF\n* Patients with hyperuricaemia defined as sUA level of \\> 6 mg/dL.\n* Patients with documented diagnosis of symptomatic HFpEF according to all of the following criteria:\n\n  1. Have NYHA functional class II-III at enrolment\n  2. Have medical history of typical symptoms/signs of HF \\> 6 weeks before enrolment\n  3. LVEF \u2265 45%\n  4. NT-proBNP \u2265 125 pg/mL (\u2265 14.75 pmol/L) at Visit 1 for patients without ongoing atrial fibrillation/flutter.\n* Patients able to exercise to near exhaustion during a CPET as exhibited by RER\n\n  \u2265 1.05 during CPET conducted during screening. If patient does not achieve RER \u2265 1.05 the CPET may be repeated once, at least 48 hours but less than 2 weeks (but before randomisation) after the initial test; in such cases the second test will serve as baseline.\n* Male or female\n\nExclusion Criteria:\n\n* eGFR \\< 30ml/min/1.73m2 (based on CKD-EPI formula)\n* Presence of any condition that precludes exercise testing\n* Known history of a documented LVEF \\< 40%\n* Probable alternative or concomitant diagnoses which in the opinion of the Investigator could account for the patient's HF symptoms and signs (eg, anaemia, hypothyroidism)\n* Known carrier of the Human Leukocyte Antigen-B (HLA-B) \\*58:01 allele: HLA-B\n\n  \\*58:01 genotyping is mandatory prior to randomization for all patients.\n* Patients diagnosed with tumor lysis syndrome or Lesch-Nyhan syndrome\n* Patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the patients' tasks associated with the protocol\n* Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardises the quality of the data to be generated\n* Current acute decompensated HF or hospitalisation due to decompensated HF \\< 4 weeks prior to enrolment\n* Myocardial infarction, unstable angina, coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting), ablation of atrial flutter/fibrillation, valve repair/replacement, implantation of a cardiac resynchronisation therapy device, stroke or transient ischemic attack within 6 months prior to enrolment.\n* Planned coronary revascularisation, ablation of atrial flutter/fibrillation and/or valve repair/replacement\n* Atrial fibrillation with persistent resting heart rate \\> 110 beats per minute.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dalane Kitzman, MD", "affiliation": "1326 Riverview Road Ext Lexington, NC 27292-1764 USA", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Granada Hills", "state": "California", "zip": "91344", "country": "United States", "geoPoint": {"lat": 34.26472, "lon": -118.52314}}, {"facility": "Research Site", "city": "Northridge", "state": "California", "zip": "91324", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Torrance", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33135", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Pembroke Pines", "state": "Florida", "zip": "33024", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "Research Site", "city": "Port Orange", "state": "Florida", "zip": "32127", "country": "United States", "geoPoint": {"lat": 29.13832, "lon": -80.99561}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Norfolk", "state": "Virginia", "zip": "23510", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Research Site", "city": "Caba", "zip": "C1006ACC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "C1119ACN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "C1425AGC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Mar del Plata", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Research Site", "city": "Mar del Plata", "zip": "B7600GNY", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Research Site", "city": "Rosario", "zip": "2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Bedford Park", "zip": "5042", "country": "Australia", "geoPoint": {"lat": -35.03333, "lon": 138.56667}}, {"facility": "Research Site", "city": "Chermside", "zip": "4032", "country": "Australia", "geoPoint": {"lat": -27.38472, "lon": 153.03062}}, {"facility": "Research Site", "city": "Geelong", "zip": "3220", "country": "Australia", "geoPoint": {"lat": -38.14711, "lon": 144.36069}}, {"facility": "Research Site", "city": "Milton", "zip": "4064", "country": "Australia", "geoPoint": {"lat": -35.31644, "lon": 150.4361}}, {"facility": "Research Site", "city": "Graz", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"facility": "Research Site", "city": "Wien", "zip": "1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Research Site", "city": "Plovdiv", "zip": "4004", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Research Site", "city": "Sofia", "zip": "1000", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Sofia", "zip": "1431", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G2J 0C4", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G3K 2P8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Bad Oeynhausen", "zip": "32545", "country": "Germany", "geoPoint": {"lat": 52.20699, "lon": 8.80365}}, {"facility": "Research Site", "city": "Berlin", "zip": "10789", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "G\u00f6ttingen", "zip": "37075", "country": "Germany", "geoPoint": {"lat": 51.53443, "lon": 9.93228}}, {"facility": "Research Site", "city": "Regensburg", "zip": "93053", "country": "Germany", "geoPoint": {"lat": 49.01513, "lon": 12.10161}}, {"facility": "Research Site", "city": "W\u00fcrzburg", "zip": "97078", "country": "Germany", "geoPoint": {"lat": 49.79391, "lon": 9.95121}}, {"facility": "Research Site", "city": "Cheongju-si", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Research Site", "city": "Gangwon-do", "zip": "26426", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Quer\u00e9taro", "zip": "76000", "country": "Mexico"}, {"facility": "Research Site", "city": "Bydgoszcz", "zip": "85-079", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Chojnice", "zip": "89-600", "country": "Poland", "geoPoint": {"lat": 53.69554, "lon": 17.55701}}, {"facility": "Research Site", "city": "Chrzan\u00f3w", "zip": "32-500", "country": "Poland", "geoPoint": {"lat": 50.13546, "lon": 19.40203}}, {"facility": "Research Site", "city": "Lublin", "zip": "20-362", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Tychy", "zip": "43-100", "country": "Poland", "geoPoint": {"lat": 50.13717, "lon": 18.96641}}, {"facility": "Research Site", "city": "Warszawa", "zip": "02-097", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "02-637", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "04-628", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Aramil", "zip": "624002", "country": "Russian Federation", "geoPoint": {"lat": 56.6977, "lon": 60.8369}}, {"facility": "Research Site", "city": "Kemerovo", "zip": "650002", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630055", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "199226", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "St Petersburg", "zip": "195067", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Tomsk", "zip": "634012", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Research Site", "city": "Brezno", "zip": "97742", "country": "Slovakia", "geoPoint": {"lat": 48.80431, "lon": 19.63631}}, {"facility": "Research Site", "city": "Lucenec", "zip": "984 01", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Research Site", "city": "Presov", "zip": "080 01", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Research Site", "city": "Svidnik", "zip": "08901", "country": "Slovakia", "geoPoint": {"lat": 49.30819, "lon": 21.5703}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Clinical Study Protocol Redacted", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5496C00005&amp;attachmentIdentifier=fce5ac49-abba-45d6-97e6-9c743db21176&amp;fileName=Clinical_Study_Protocol_redacted.pdf&amp;versionIdentifier="}, {"label": "CSR_synopsis_redacted", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5496C00005&amp;attachmentIdentifier=99f91757-f330-4480-b3fa-db052dbed5ca&amp;fileName=Clinical_Study_Report_synopsis_redacted.pdf&amp;versionIdentifier="}, {"label": "Statistical Analysis Plan-redacted", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5496C00005&amp;attachmentIdentifier=d1b3f66a-e0b3-4c29-bd75-cbabdfcc4f19&amp;fileName=Statistical_Analysis_Plan-redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects who met all the of inclusion criteria and none of the exclusion criteria were randomized to a study treatment. Study treatment was titrated over 8 weeks. Colchicine prophylaxis was given during the titration period and during the first 4 weeks of treatment at target dose (12 weeks total) and was distributed as available, currently 500 \u03bcg within the European Union (EU) and 600 \u03bcg within the United States (US).", "recruitmentDetails": "475 subjects were screened between May 19, 2020, and July 16, 2021, at 59 sites in 12 different countries. Of those screened, 159 were randomized into the study and received treatment, 53 in each arm of the study.", "groups": [{"id": "FG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "FG001", "title": "Allopurinol", "description": "300 mg Allopurinol"}, {"id": "FG002", "title": "Placebo", "description": "0 mg placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}, {"groupId": "FG001", "numSubjects": "53"}, {"groupId": "FG002", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "49"}, {"groupId": "FG002", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Full Analysis Set includes all subjects who have been randomized to study treatment.", "groups": [{"id": "BG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "BG001", "title": "Allopurinol", "description": "300 mg Allopurinol"}, {"id": "BG002", "title": "Placebo", "description": "0 mg placebo"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "53"}, {"groupId": "BG003", "value": "159"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.6", "spread": "9.04"}, {"groupId": "BG001", "value": "70.6", "spread": "6.98"}, {"groupId": "BG002", "value": "67.5", "spread": "9.77"}, {"groupId": "BG003", "value": "69.2", "spread": "8.72"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "56"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "103"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "13"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "49"}, {"groupId": "BG003", "value": "146"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "48"}, {"groupId": "BG003", "value": "140"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "14"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model)", "description": "Mean change from baseline in peak VO2 at Week 32 between the treatment groups was compared using change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and baseline peak VO2 included as covariate.\n\nH0: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs placebo) = 0 Ha: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs placebo) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.\n\nSince this was the first test in the hierarchical test sequence and endpoint was not rejected at a two-sided 0.05 level, the testing sequence did not continue.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL/kg/min", "timeFrame": "From baseline to Week 32", "groups": [{"id": "OG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "OG001", "title": "Placebo", "description": "0 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "-0.56", "upperLimit": "1.10"}, {"groupId": "OG001", "value": "0.37", "lowerLimit": "-0.45", "upperLimit": "1.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.862", "statisticalMethod": "ANCOVA", "statisticalComment": "Model included change from baseline as the dependent variable, treatment as the independent variable and baseline peak VO2 as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.28", "ciUpperLimit": "1.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad+ Allopurinol Compared to Allopurinol Monotherapy (ANCOVA Model)", "description": "Mean change from baseline in peak VO2 at Week 32 between the treatment groups was compared using change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and baseline peak VO2 included as covariate.\n\nH0: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs allopurinol) = 0 Ha: Difference in mean change from baseline in peak VO2 (verinurad + allopurinol vs allopurinol) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL/Kg/min", "timeFrame": "From baseline to Week 32", "groups": [{"id": "OG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "OG001", "title": "Allopurinol Monotherapy", "description": "300 mg allpurinol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "-0.56", "upperLimit": "1.10"}, {"groupId": "OG001", "value": "-0.17", "lowerLimit": "-1.03", "upperLimit": "0.69"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.472", "statisticalMethod": "ANCOVA", "statisticalComment": "Model included change from baseline as the dependent variable, treatment as the independent variable and baseline peak VO2 as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.76", "ciUpperLimit": "1.64"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 32 in KCCQ-TSS in Verinurad+ Allopurinol Compared to Placebo (MMRM)", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item assessment that measures the patient's perception of their health status, which includes heart failure-related symptoms (frequency, burden, recent change), impact on physical and social function, self-efficacy and knowledge, and how the patient's heart failure affects their quality of life. The Total Symptom Score (TSS) averages the frequency domain and the symptom burden domain subscales, which each range from 0 to 100. The TSS ranges from 0-100 (higher scores = better health status).\n\nMean change from baseline in KCCQ-TSS at Week 32 between the treatment groups was compared using MMRM analysis, with change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS included as covariates.\n\nThe number analyzed at each timepoint represents the number of subjects with data at each visit.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Scores on a scale", "timeFrame": "From baseline to Week 22 and Week 32", "groups": [{"id": "OG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "OG001", "title": "Placebo", "description": "0 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Week 22", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "lowerLimit": "-4.08", "upperLimit": "5.08"}, {"groupId": "OG001", "value": "3.55", "lowerLimit": "-1.29", "upperLimit": "8.39"}]}]}, {"title": "Week 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.31", "lowerLimit": "0.28", "upperLimit": "8.33"}, {"groupId": "OG001", "value": "1.16", "lowerLimit": "-3.02", "upperLimit": "5.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: Difference in mean change from baseline in KCCQ-TSS (verinurad + allopurinol vs placebo) = 0 Ha: Difference in mean change from baseline in KCCQ-TSS (verinurad + allopurinol vs placebo) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.", "nonInferiorityType": "OTHER", "pValue": "0.287", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model included treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS as covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.65", "ciUpperLimit": "8.94"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 32 in KCCQ-TSS in Verinurad+ Allopurinol Compared to Allopurinol Monotherapy (MMRM)", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item assessment that measures the patient's perception of their health status, which includes heart failure-related symptoms (frequency, burden, recent change), impact on physical and social function, self-efficacy and knowledge, and how the patient's heart failure affects their quality of life. The Total Symptom Score (TSS) averages the frequency domain and the symptom burden domain subscales, which each range from 0 to 100. The TSS ranges from 0-100 (higher scores = better health status).\n\nMean change from baseline in KCCQ-TSS at Week 32 between the treatment groups was compared using MMRM analysis, with change from baseline (i.e., week 32 value - baseline value) as the dependent variable, treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS included as covariates.\n\nThe number analyzed at each timepoint represents the number of subjects with data at each visit.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Scores on a scale", "timeFrame": "From baseline to Week 22 and Week 32", "groups": [{"id": "OG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol"}, {"id": "OG001", "title": "Allopurinol Monotherapy", "description": "300 mg allopurinol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Week 22", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "lowerLimit": "-4.08", "upperLimit": "5.08"}, {"groupId": "OG001", "value": "2.85", "lowerLimit": "-1.91", "upperLimit": "7.62"}]}]}, {"title": "Week 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.31", "lowerLimit": "0.28", "upperLimit": "8.33"}, {"groupId": "OG001", "value": "4.45", "lowerLimit": "0.34", "upperLimit": "8.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: Difference in mean change from baseline in KCCQ-TSS (verinurad + allopurinol vs allopurinol) = 0 Ha: Difference in mean change from baseline in KCCQ-TSS (verinurad + allopurinol vs allopurinol) \u2260 0\n\nA hierarchical test sequence was used for the confirmatory analysis of the primary and secondary objectives in order to address the issue of multiple testing and control the Type I error rate at an overall two-sided 0.05 level.", "nonInferiorityType": "OTHER", "pValue": "0.960", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model included treatment as the independent variable and visit, visit by treatment, and baseline KCCQ-TSS as covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.90", "ciUpperLimit": "5.61"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Adverse events were collected with onset date on or after first dose and up to the end of the study (week 36). Serious adverse events were collected with onset date on or after the signing of the informed consent form and up to the end of the study (week 36).", "description": "All adverse events reported are treatment emergent with onset on or after the first dose and up to the end of the study (week 36).", "eventGroups": [{"id": "EG000", "title": "Verinurad + Allopurinol", "description": "12 mg verinurad + 300 mg allopurinol", "deathsNumAffected": 1, "deathsNumAtRisk": 53, "seriousNumAffected": 10, "seriousNumAtRisk": 53, "otherNumAffected": 24, "otherNumAtRisk": 53}, {"id": "EG001", "title": "Allopurinol", "description": "300 mg Allopurinol", "deathsNumAffected": 2, "deathsNumAtRisk": 53, "seriousNumAffected": 10, "seriousNumAtRisk": 53, "otherNumAffected": 26, "otherNumAtRisk": 53}, {"id": "EG002", "title": "Placebo", "description": "0 mg placebo", "deathsNumAffected": 1, "deathsNumAtRisk": 53, "seriousNumAffected": 9, "seriousNumAtRisk": 53, "otherNumAffected": 20, "otherNumAtRisk": 53}], "seriousEvents": [{"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Oesophageal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Anal fissure haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Duodenitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Gastrointestinal necrosis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Obstructive pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Rectal prolapse", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "COVID-19 pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Clostridium difficile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 8, "numAffected": 5, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}], "otherEvents": [{"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Rales", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 53}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca Clinical Study Information Center", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-09-20", "uploadDate": "2023-04-26T05:57", "filename": "Prot_000.pdf", "size": 6001307}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-06-02", "uploadDate": "2023-04-26T05:57", "filename": "SAP_001.pdf", "size": 2124727}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Hong Kong"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-05-19", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000493", "term": "Allopurinol"}, {"id": "C000628929", "term": "Verinurad"}], "ancestors": [{"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000006074", "term": "Gout Suppressants"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000016166", "term": "Free Radical Scavengers"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M3834", "name": "Allopurinol", "asFound": "African", "relevance": "HIGH"}, {"id": "M262891", "name": "Verinurad", "asFound": "Stage IV adult diffuse small cleaved cell lymphoma", "relevance": "HIGH"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}